Our portfolio comprises more than a dozen investments in the life science industries, predominantly in the United States and Europe, which can cure disease, reduce cost of care, and improve quality of life.
Olipan seeks out highly innovative opportunities in the Central Nervous System, Cardiac, and Oncology sub-sectors of the life science industry.
Olipan invests 60% of its funds in seed and early stage biomedical technology companies developing medical devices, bio-pahramaceuticals, healthcare services and digital infrastructure. We have been successful in identifying a number of investments that have gone on to IPO on the NASDAQ market, or exit via sale to a strategic partner. To learn more about some of successful exits, Click Here >
In the United States, Olipan is also a Limited Partner in Ascent Biomedical Ventures, a leading New York-based venture capital firm focused on early stage investment and development of biomedical companies, with strong connections to Deerfield which has over $14B assets under management.
In Europe, Olipan is a founder shareholder in CEBINA The Central European Biotech Incubator & Accelerator at the University of Vienna’s Campus Biotech, which supports innovative biotechnology companies focused on inflammation, neurology and ageing. Olipan is also a Limited Partner in Danube Labs, which brings together CEBINA’s strength in scientific innovation and entrepreneurship, with Evotec’s industry-leading drug discovery and development expertise to accelerate academic life science research projects with a focus on Central and Eastern European Universities and Research Institutes.
Olipan invests 40% of its funds in residential real estate in Europe, and public equities in Europe and the United Sates.
Olipan Investments (TdT5) Inc. is managed by an executive board reporting to the Chairman.
The Board is comprised of a group of experienced Austrian and English senior Swiss Bank Directors, Accountants, Professional Trust Directors, and Private Equity experts, including:
CHRISTIAN WAGNER – holds a Master’s Degree in Business Administration from the University of Lausanne HEC, Switzerland. He started his career at Bank Morgan Grenfell & Co in London and Geneva, where he acted as Deputy CEO, and was Deputy Chairman at Banque Heritage SA in Geneva until 2021.
IAN LEDGER – graduated from the University of Wales prior to joining Barclays Bank, Rothschild & Co, and Kleinwort Benson. He established Landmark Group in Monaco in 1985 where he is a Director and Shareholder. He has vast corporate experience of trusts and family administration.
PATRICK AISHER – is Chairman of Kinled Holding in Hong Kong, which retains a portfolio of 100+ investments in the life science, digital and financial technology industries. He is also a Director of Aleva Neurotherapeutics SA, PreComb Therapeutics AG, and Sonect AG in Switzerland, and CEBINA - the Central European Biotechnology Incubator and Accelerator, in Vienna, Austria.